Isoprostanes, Novel Markers of Oxidative Injury, Help Understanding the Pathogenesis of Neurodegenerative Diseases

Neurochemical Research

Volumn 25, Issue 9-10, 2000, Pages 1357-1364

  Greco, Anita ^a   Minghetti, Luisa ^a   Levi, Giulio ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Free radicals; Isoprostanes; Lipid peroxidation; Neurodegeneration; Neuroprostanes; Oxidative stress

Indexed keywords

DRUG DERIVATIVE; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE;

ALZHEIMER DISEASE; ANIMAL; BRAIN; CEREBROSPINAL FLUID; DEGENERATIVE DISEASE; HUMAN; HUNTINGTON CHOREA; LIPID PEROXIDATION; METABOLISM; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; REVIEW;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DINOPROST; HUMANS; HUNTINGTON DISEASE; LIPID PEROXIDATION; MULTIPLE SCLEROSIS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0034302893     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1007608615682     Document Type: Article

References (63)

1. Chan, P. H. 1996. Role of oxidants in ischemic brain damage. Stroke 27:1124-1129.
2. Weber, G. F. 1994. The pathophysiology of reactive oxygen intermediates in the central nervous system. Medical Hypotheses 43:223-230.
3. Jenner, P. 1994. Oxidative damage in neurodegenerative disease. Lancet 344:796-798.
4. Olanow, C. W. 1993. A radical hypothesis for neurodegeneration. Trends Neurosci. 16:439-444.
5. Farooqui, A. A. and Horrocks, L. A. 1998. Lipid peroxides in the free radical pathophysiology of brain diseases. Cell. Mol. Neurobiol. 18:599-608.
6. Delanty, N. and Dichter, M. A. 1998. Oxidative injury in the nervous system. Acta Neurol. Scand. 98:145-153.
7. Halliwell, B. 1989. Oxidants and the central nervous system: some fundamental questions. Acta Neurol. Stand. 126:23-33.
8. Moore, K. and Roberts II, L. J. 1998. Measurement of lipid peroxidation. Free Rad. Res. 28:659-671.
9. Yeo, H. C., Helbock, H. J., Chyu, D. W., and Ames, B. N. 1994. Assay of malondialdehyde in biological fluids by gas chromatography-mass spectrometry. Anal. Biochem. 220:391-396.
10. Cailleux, A. and Allain, P. 1993: Is pentane a normal constituent of human breath? Free Rad. Res. Commun. 18:323-327.
11. Halliwell, B. and Gutteridge, M. C. 1987. The measurement of free radical reactions in human. FEBS Lett. 213:9-14.
12. Halliwell, B., Gutteridge, M. C., and Cross, C. E. 1992. Free radicals, antioxidants, and human diseases: where are we now? J. Lab. Clin. Med. 119:598-618.
13. Rimbach, G., Hohler, D., Fischer, A., Roy, S., Virgili, F., Pallauf, J., and Packer, L. 1999. Methods to assess free radicals and oxidative stress in biological systems. Arch. Tierernahr. 52: 203-222.
14. 2-like compounds are produced in vivo in humans by a non-cyclooxy-genase, free radical-catalysed mechanism. Proc. Natl. Acad. Sci. USA 87:9383-9387.
15. Lawson, J. A., Rokach, J., and Fitzgerald, G. A. 1999. Isoprostanes: Formation, analysis and use as indices of lipid peroxidation in vivo. J. Biol. Chem. 274:24441-24444.
16. 4-isoprostanes: a novel class of prostanoids formed during peroxidation of docosahexaenoic acid (DHA). Biochem. Biophys. Res. Commun. 242:338-344.
17. Roberts II, L. J., Montine, T. J., Markesbery, W. R., Tapper, A. R., Hardy, P., Chemtob, S., Dettbarn, W. D., and Morrow, J. D. 1998. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem. 273:13605-13612.
18. 2α in pericardial fluid of patients with heart failure. Circulation. 97: 1536-1539.
19. 2-isoprostane and 4-hydroxynonenal excretion in human bile of patients with biliary tract and pancreatic disorders. Am. J. Gastroenterol. 92:2069-2072.
20. Montuschi, P., Ciabattoni, G., Paredi, P., Pantelidis, P., duBois, R. M., Kharitonov, S. A., and Barnes, P. J. 1998. 8-Isoprostane as a Biomarker of Oxidative Stress in Interstitial Lung Diseases. Am. J. Respir. Crit. Care Med. 158:1524-1527.
21. 2-isoprostane levels are increased in Alzheimer's disease. Ann. Neurol. 44:410-413.
22. 2α excretion in man. J. Pharmacol. Exp. Ther. 275:94-100.
23. Praticò, D., Lawson, J., and FitzGerald, G. A. 1995. Cycooxygenase dependent formation of 8-epi-PGF2α in human platelets. 1995. J. Biol. Chem. 270:9800-9808.
24. 2-isoprostane formation. Br. J. Pharmacol. 118:1285-1293.
25. Reilly, M. P., Delanty, N., Lawson, J. A., and Fitzgerald, G. A. 1996. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 94:19-25.
26. Ciabattoni, G., Patrignani, P., Panara, M. R., Greco, A., Cipollone, F., Davi', G., Di Minno, G., Coppola, A., and Patrono, C. 1996. Studies of isoprostane biosynthesis in man. Pages 111-115, in Folco, Samuelsson, Maclouf and Velo (eds.), Eicosanoids: from Biotechnology to Therapeutic Applications, Plenum Press, New York.
27. Waugh, R. J. and Murphy, R. C. 1996. Mass spectrometric analysis of four reigioisomers of formed by free radicals oxidation of arachidonic acid. J. Am. Soc. Mass. Spectrom. 7:490-499.
28. Greco, A., Minghetti, L., Sette, G., Fieschi, C., and Levi, G. 1999. Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 53:1876-1879.
29. 2-isoprostane in human and experimental transmissible spongiform encephalopaties. J. Neuropathol. Exp. Neurol. 59:20-25.
30. Reilly, M. P., Lawson, J. A., and Fitzgerald, G. A. 1998. Eicosanoids and Isoecosanoids: indices of cellular function and oxidant stress. J. Nutr. 128:434S-438S.
31. Morrow, J. D. and Roberts, L. J. 1997. The isoprostanes: unique bioactive products of lipid peroxidation. Prog. Lipid Res. 36:1-21.
32. Roberts II, L. J. and Morrow, J. D. 1997. The generation and actions of isoprostanes. Biochem. Biophys. Acta 1345:121-135.
33. 2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins 44: 155-163.
34. 2 receptors in human platelets. J. Pharmacol. Exp. Ther. 270:1192-1196.
35. 2α is not mediated by thromboxane receptor isoforms. J. Biol. Chem. 271: 14916-14924.
36. Elmhurst, J. L., Betti, P. -A., and Rangachari, P. K. 1997. Intestinal effects of isoprostanes: evidence for the involvement of prostanoid EP and TP receptors. J. Pharmacol. Exp. Ther. 282:1198-1205.
37. Souvignet, C., Cracowski, J. L., Stanke-Labesque, F., and Bessard, G. 2000. Are isoprostanes a clinical marker for antioxidant drug investigation? Fundam. Clin. Pharmacol. 14:1-10.
38. Awad, J. A., Roberts II, L. J., Burk, R. F., and Morrow, J. D. 1996. Isoprostanes: prostaglandin-like compounds formed in vivo independently of cyclooxygenase: use as clinical indicators of oxidant damage. Gastroenterol. Clin. North Am. 25:409-427.
39. Roberts II, L. J., Brame, C. J., Chen, Y., and Morrow, J. D. 1999. Novel eicosanoids. Isoprostanes and related compounds. Methods Mol. Biol. 120:257-285.
40. Patrono, C. and Fitzgerald, G. A. 1997. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Atheroscler. Thromb. Vasc. Biol. 17:2309-2315.
41. Liu, T., Stern, A., Roberts II, L. J., and Morrow, J. D. 1999. The isoprostanes: novel prostaglandin-like products of the free radical-catalyzed peroxidation of AA. Biomed. Sci. 6:226-35.
42. 2-isoprostane concentration in probable AD. Neurology 52: 562-565.
43. 4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. J. Neurochem. 72:734-740.
44. 2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 12:1777-1783.
45. 2-isoprostane levels are increased in Alzheimer's disease: evidence for increased oxidative stress in vivo. Alzheimer's Report 2:277-282.
46. 2-isoprostanes are elevated in Huntington's disease. Neurology 23:1104-1105.
47. Markesbery, W. R. and Carney, J. M. 1999. Oxidative alteration in Alzheimer's disease. Brain Pathol. 9:133-146.
48. Mattson, M. P. 1997. Central role of oxyradicals in the mechanism of amyloid β-peptide cytotoxicity. Alzheimer's Disease Review 2:1-14.
49. Paganini-Hill, A. and Henderson, V. W. 1994. Estrogen deficiency and risk of Alzheimer's disease in women. Am. J. Epidemiol. 140: 256-261.
50. Goodman, Y., Bruce, A. J., Cheng, B., and Mattson, M. P. 1996. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid b-peptide toxicity in hippocampal neurons. J. Neurochem. 66:1836-1844.
51. 2-isoprostanes, in vivo markers of lipid peroxidation. J. Neurochem. 73:736-41.
52. 2α as a marker of amyloid β-peptide-induced oxidative damage. J. Neurochem. 72:1146-1153.
53. Smith, K. J., Kapoor, R., and Felts, P. A. 1999. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol. 9: 69-92.
54. LeVine, S. M. 1992. The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Med. Hypotheses 39:271-274.
55. Fieschi, C., Gasperini, C., Ristori, G., Bastianello, S., Girmenia, F., Leuzzi, V., Buttinelli, C., and Rasura, M. 1995. Patients with clinically definite multiple sclerosis, white matter abnormalities on MRI, and normal CSF: if not multiple sclerosis, what is it? J. Neurol. Neurosurg. Psychiatry 58:255-256.
56. Kurtzke, J. F. 1983. Rating neurological impairment in MS. Neurology 33:1444-1452.
57. van der Veen, R. C. and Roberts II, L. J. 1999. Contrasting roles for nitric oxide and peroxynitrite in the peroxidation of myelin lipids. J. Neuroimmunol. 95:1-7.
58. Browne, S. E., Ferrante, R. J., and Seal, M. F. 1999. Oxidative stress in Huntington's Disease. Brain Pathol. 9:147-163.
59. Will, R. G., Alpérovitch, A., Poser, S., Pocchiari, M., Hofman, A., Mitrova, E., de Silva, R., D'Alessandro, M., Delasnerie-Laupretre, N., Zerr, I., and van Duijn, C. 1998. Descriptive epidemiology of Creutzfeldt-Jakob disease in six European countries, 1993-1995. Ann. Neurol. 43:763-767.
60. McGeer, P. L. and McGeer, E. G. 1995. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. 21:195-218.
61. Perry, V. H., Bolton, S. J., Antony, D. C., and Betmouni, S. 1998. The contribution of inflammation to acute and chronic neurodegeneration. Res. Immunol. 149:721-725.
62. Brown, D. R., Schmidt, B., and Kretzschmar, H. A. 1996. Role of microglia and host prion protein in neurotoxicity of a prion protein fragment. Nature 380:345-347.
63. Giese, A., Brown, D. R., Groschup, M. H., Feldmann, C., Haist, I., and Kretzschmar, H. A. 1998. Role of microglia in neuronal cell death in prion disease. Brain Pathol. 8:449-457.